Nuvo is uniquely positioned to develop transdermal product candidates. Firstly, Nuvo has a slate of proprietary penetration enhancer formulations, multiplexed molecular penetration enhancers ("MMPE"s), that are capable of interacting with skin, at the molecular level, so as to modify its permeability for a given drug molecule. Secondly, Nuvo operates proprietary high throughput experimentation ("HTE") platforms that allow Nuvo scientists to screen, rapidly, how large libraries of formulations perform in skin applications^[1].

Prospective Benefits

Nuvo's MMPE^™ technology is broad-based, in that the skin barrier can be modified by molecular means for a wide range of drug molecules, or indeed other actives.

Nuvo is focused primarily on the topical treatment of pain, particularly in cases where changing the dosage form from oral to topical provides the possibility of full clinical benefit, but with reduced whole-body exposure and fewer side effects. The company is also pursuing other indication classes, primarily through collaborations with other partners.

The company’s HTE platforms also have practical utility for diverse pharmaceutical, cosmetic, personal care, diagnostic and medical device applications, in which formulations suitable for modulating one or more properties of the skin, such as permeability, need to be developed. Rapid Optimized Transdermal Formulation Development